Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial-Reference-Cited by-同舟云学术

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Published:2021-03 Issue: Volume:233 Page:141-148
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Sarraju Ashish^ORCID,Li JingWei,Cannon Christopher P.^ORCID,Chang Tara I.,Agarwal Rajiv,Bakris George,Charytan David M.^ORCID,de Zeeuw Dick,Greene Tom,Heerspink Hiddo J.L.,Levin Adeera,Neal Bruce,Pollock Carol,Wheeler David C.^ORCID,Yavin Yshai,Zhang Hong,Zinman Bernard,Perkovic Vlado,Jardine Meg,Mahaffey Kenneth W.

Funder

Janssen Research and Development

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference10 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med.,2015

2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med.,2017

3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med.,2019

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med.,2019

5. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med.,2019

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07

2. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

3. Specific Gravity Improves Identification of Clinically Significant Quantitative Proteinuria from the Dipstick Urinalysis;Kidney360;2024-04-26

4. Improving Kidney Disease Care: One Giant Leap for Nephrology;Biomedicines;2024-04-09

5. Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis;American Journal of Cardiovascular Drugs;2024-04-08